EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antiphospholipid syndrome in an adolescent with refractory immune thrombocytopenia and massive central venous thrombosis

Matylda Marcelina Mikołajczyk, Wioletta Bal, Gabriela Mastej-Witek, Radosław Chaber

European Journal of Clinical and Experimental Medicine · 25.06.2026 · 24 (2)

DOI: 10.15584/ejcem.2026.2.19 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical and Experimental Medicine, online erschienen am 25.06.2026. Verfasst von Matylda Marcelina Mikołajczyk und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and aim. Immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) may coexist, creating a clinical paradox of simultaneous bleeding risk and thrombophilia. In children and adolescents, APS may remain unrecognised for years when thrombocytopenia dominates the early course. The thrombotic risk associated with thrombopoietin receptor agonists (TPO-RAs) in this setting remains uncertain. Description of the case. A 17-year-old boy with refractory ITP during romiplostim therapy developed massive upper-extremity and central venous thrombosis with near-complete superior vena cava obstruction. Persistent lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibody positivity established APS. He was treated with heparin, alteplase, and long-term warfarin plus low-dose aspirin, while romiplostim was continued to support safe anticoagulation. No recurrent thrombosis or major bleeding was observed during 20 months of follow-up. Conclusion. Thrombocytopenia does not protect against thrombosis in APS. In adolescents with chronic or refractory ITP, especially when vascular symptoms, unexplained prolonged aPTT, or other autoimmune red flags are present, targeted antiphospholipid antibody testing should be considered. Management of combined ITP and APS requires individualized balancing of anticoagulation and platelet support, with vitamin K antagonists remaining the preferred long-term anticoagulant strategy in high-risk APS.

Zitieren

APA

Mikołajczyk, M. M., Bal, W., Mastej-Witek, G., & Chaber, R. (2026). Antiphospholipid syndrome in an adolescent with refractory immune thrombocytopenia and massive central venous thrombosis. European Journal of Clinical and Experimental Medicine, 24(2). https://doi.org/10.15584/ejcem.2026.2.19

Vancouver

Mikołajczyk MM, Bal W, Mastej-Witek G, Chaber R. Antiphospholipid syndrome in an adolescent with refractory immune thrombocytopenia and massive central venous thrombosis. European Journal of Clinical and Experimental Medicine. 2026;24(2). doi:10.15584/ejcem.2026.2.19

BibTeX
@article{Mikoajczyk2026,
  author = {Mikołajczyk, Matylda Marcelina and Bal, Wioletta and Mastej-Witek, Gabriela and Chaber, Radosław},
  title = {Antiphospholipid syndrome in an adolescent with refractory immune thrombocytopenia and massive central venous thrombosis},
  journal = {European Journal of Clinical and Experimental Medicine},
  year = {2026},
  volume = {24},
  number = {2},
  doi = {10.15584/ejcem.2026.2.19}
}
Kostenlos starten →